UBS Starts Galecto (GLTO) at Buy Feb 17, 2026 06:27AM
Galecto Inc. (GLTO) files mixed shelf Feb 10, 2026 04:05PM
LifeSci Capital Starts Galecto (GLTO) at Outperform Feb 2, 2026 08:22AM
Galecto plans drug trials for blood cancer treatments in 2026 Jan 12, 2026 08:02AM
Leerink Partners Starts Galecto (GLTO) at Outperform Jan 7, 2026 07:20AM


Dec 16, 2025 04:58PM Galecto Inc. (GLTO) files for 60.51M share offering by selling stockholders
Dec 8, 2025 07:49AM Galecto (GLTO) PT Raised to $36 at Guggenheim
Dec 1, 2025 12:35AM Guggenheim Starts Galecto (GLTO) at Buy
Nov 10, 2025 07:19AM Galecto completes Damora acquisition with $285 million funding round
Nov 7, 2025 04:35PM Galecto Inc. (GLTO) Misses Q3 EPS by 236c
May 9, 2025 04:02AM Galecto Inc. (GLTO) Reports Q1 Loss of $1.92
Oct 17, 2024 07:23AM Galecto (GLTO) PT Raised to $10 at Oppenheimer
Oct 15, 2024 08:32AM Galecto Inc. (GLTO) Appoints Amy Wechsler to its Board
Oct 7, 2024 08:46AM Galecto (GLTO) Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
Aug 28, 2024 09:00AM Galecto Inc. (GLTO) Announces Reverse Stock Split
Jun 10, 2024 06:18AM Galecto (GLTO) PT Lowered to $9 at Oppenheimer